Clinical trials: Vascular Health
Diabetes Mellitus, Type 2
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to compare the effect of ticagrelor versus placebo in patients with Type 2 Diabetes Mellitus.
- Trial name
- THEMIS (NCT01991795)
- Testing
- Ticagrelor 60 mg
- Where
- 1,237 sites in United States, Argentina and 41 more
- Volunteers
- 19,271 people
- Sponsor
- AstraZeneca
Arterial Occlusive Diseases, Atherosclerosis
A Real World Evaluation of the ELUVIA Stent in Subjects With Lesions Located in the Femoropopliteal Arteries
The REGAL study is a European, prospective, multi-center Post-Market Clinical Follow-up (PMCF) trial providing additional data including health economics data to support the use of the ELUVIA stent in the treatment of lesions…
- Conditions
- Arterial Occlusive Diseases, Atherosclerosis, Vascular Diseases, Arteriosclerosis
- Trial name
- REGAL (NCT03037411)
- Testing
- Peripheral stenting
- Where
- 23 sites in Austria, Belgium and 3 more
- Volunteers
- 291 people
- Sponsor
- Boston Scientific Corporation
Thromboembolism
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer
The purpose of this study is to evaluate the health care resource utilization and costs associated with treating patients diagnosed with cancer and venous thromboembolism with apixaban or low molecular weight heparin.
- Trial name
- NCT05643885
- Where
- United States
- Volunteers
- 7,304 people
- Sponsor
- Pfizer
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Vascular Access Complication
Prospective Feasibility Trial of AccuCath 2.25" Blood Control (BC) Placed in Difficult Access Patients in the Emergency Department
Study objective is to evaluate user preference, time for procedure, insertion success rates, complications, completion of therapy and dwell time of the AccuCath 2.25" BC device placed in difficult IV access patients in the…
- Trial name
- NCT02449798
- Testing
- AccuCath 2.25" BC Intravascular Catheter
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- C. R. Bard
Hypertension
Digital Health for Medication Adherence Among African Americans With Hypertension
The proposed Phase 1 project aims to develop and test Memento.HTN, an individually-tailored, culturally sensitive digital health intervention comprised of a provider platform and linked patient SMS (short message service) text…
- Trial name
- NCT05009004
- Testing
- text messages to support medication adherence
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Environment and Health Group, Inc.
Pulmonary Hypertension (World Health Organization Group 2), Heart Failure
A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2
This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2
- Trial name
- Re-PHIRE (NCT05737940)
- Testing
- AZD3427
- Where
- 60 sites in United States, Austria and 12 more
- Volunteers
- 260 people
- Sponsor
- AstraZeneca
Pulmonary Arterial Hypertension
A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)
The objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension [PAH] therapy) versus placebo (plus maximum…
- Trial name
- ZENITH (NCT04896008)
- Testing
- Sotatercept
- Where
- 57 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Dementia, Alzheimer Disease
Efficacy Study of Kinto Care Coaching for Dementia Family Caregivers
The goal of this clinical trial is to evaluate Kinto's Care Coaching intervention for dementia caregivers. The main questions it aims to answer are: Does the intervention help caregivers to address their general caregiving goals…
- Conditions
- Dementia, Alzheimer Disease, Lewy Body Disease, Vascular Dementia
- Trial name
- NCT05916664
- Testing
- Kinto Care Coaching
- Where
- United States
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- Kinto